Boston, United States
argenx, a prominent name in the Biotechnology and Health and Wellness industries, is firmly positioned as a global leader in immunology. Established in 2008, the company is headquartered in the United States and is driven by its slogan, United in our commitment to improve the lives of patients.
Specializing in severe autoimmune diseases, argenx collaborates with academic leaders via its Immunology Innovation Program (IIP), effectively translating immunology innovations into a robust portfolio of pioneering antibody-based therapies.
A noteworthy aspect of its financial trajectory is the substantial €979.60M Post-IPO Equity investment secured on 19 July 2023. This influx of capital is anticipated to bolster its R&D capabilities and expedite the development of its immunology solutions.
For investors, argenx represents a strategic opportunity to participate in the future of biotechnological advancements tailored towards transformative patient outcomes in autoimmune diseases.
